{"nctId":"NCT02752074","briefTitle":"A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)","startDateStruct":{"date":"2016-06-21","type":"ACTUAL"},"conditions":["Melanoma"],"count":706,"armGroups":[{"label":"Pembrolizumab + Epacadostat","type":"EXPERIMENTAL","interventionNames":["Drug: pembrolizumab + epacadostat"]},{"label":"Pembrolizumab + Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: pembrolizumab + placebo"]}],"interventions":[{"name":"pembrolizumab + epacadostat","otherNames":[]},{"name":"pembrolizumab + placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have histologically or cytologically confirmed melanoma\n* Have unresectable Stage III or Stage IV melanoma, as per AJCC staging system not amenable to local therapy\n* A minimum of 1 measurable lesion by CT or MRI\n* Provide a baseline tumor biopsy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\n\nExclusion Criteria:\n\n* Has received prior systemic treatment for unresectable or metastatic melanoma (except BRAF directed therapy)\n* Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or IDO1 inhibitor or any other antibody or drug specifically targeting checkpoint pathways other than anti-CTLA-4 which is permitted in the adjuvant setting\n* Has received prior adjuvant therapy, monoclonal antibody or an investigational agent or device within 4 weeks or 5 half-lives (whichever is longer)\n* Has an active infection requiring systemic therapy\n* Has known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)\n* Has known history of or is positive for Hepatitis B or Hepatitis C\n* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival","description":"Progression-free survival, defined as the time from date of randomization until the earliest date of disease progression, as determined by independent central review of objective radiographic disease assessments per RECIST 1.1, or death from any cause, whichever comes first.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null},{"groupId":"OG001","value":"4.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Overall Survival (OS) Rate at 6 Months","description":"Defined as time from date of randomization to date of death due to any cause. OS was calculated using product-limit (Kaplan-Meier) method for censored data.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.1","spread":null},{"groupId":"OG001","value":"87.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR)","description":"Objective response rate (ORR) is defined as the percentage of the participants in the analysis population who have a confirmed complete response (CR) or partial response (PR) based on RECIST 1.1 by independent central review.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"111","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety and Tolerability, as Assessed by Percentage of Participants With Adverse Events","description":"Safety and tolerability, as assessed by percentage of participants with adverse events and changes in laboratory parameters.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"346","spread":null},{"groupId":"OG001","value":"345","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR)","description":"Defined as the time from the earliest date of qualifying response until earliest date of disease progression, per RECIST v1.1, or death from any cause, whichever comes first. Includes participants with complete response or partial response.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Apparent Oral Clearance (CL/F) of Epacadostat","description":"Defined as oral dose clearance.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.8","spread":"17.5"}]}]}]},{"type":"SECONDARY","title":"Apparent Volume of Distribution (Vd/F) of Epacadostat","description":"Apparent volume of distribution after administration.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":"22.5"}]}]}]},{"type":"SECONDARY","title":"Clearance (CL) of Pembrolizumab","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Volume of Distribution (V) of Pembrolizumab","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Formation of Anti-pembrolizumab Antibodies","description":"Evaluate the measurement of anti-drug antibodies (ADA).","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":99,"n":353},"commonTop":["Fatigue","Diarrhoea","Nausea","Pruritus","Rash"]}}}